Navamedic

M&A Activity • Jul 15, 2025

Navamedic ASA: Closing of the transaction to acquire the business of dne pharma

Navamedic ASA: Closing of the transaction to acquire the business of dne pharma

Oslo, 15 July 2025: Reference is made to the stock exchange announcement

published by Navamedic ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") on

23 June 2025, regarding Navamedic entering into an asset purchase agreement for

the acquisition of the business of dne pharma AS for a total consideration of up

to NOK 225 million, whereby NOK 185 million is payable at closing, and the

remaining NOK 40 million is payable in two tranches subject to achievement of

certain agreed sales volumes for the acquired products (the "Transaction").

Navamedic is pleased to announce that the Transaction has today been

successfully completed.

The Acquisition encompasses dne pharma's business, including product portfolio,

key employees and all essential contracts of the business, intellectual

property, licenses, and distribution agreements. The product portfolio includes

prominent products such as Ventizolve® (intranasal naloxone spray for opioid

overdose reversal), Levopidon® (levomethadone), and Metadon Dne (methadone) for

opioid substitution therapy. The acquired business will be integrated into

Navamedic's existing commercial platform, enabling rapid market access and

geographic expansion across the Nordics and selected European markets.

"This acquisition represents a significant step in our strategic expansion into

the rapidly growing field of addiction treatment and is well aligned with our

long-term growth ambitions. Thanks to the strong collaboration among all parties

involved, the transaction was completed in a smooth and efficient manner. We are

pleased that the General Meeting unanimously approved the Rights Issue

yesterday, and we are sincerely grateful for the continued support of Kistefos

and the other underwriters," said Kathrine Gamborg Andreassen, CEO of Navamedic.

The Acquisition is financed through a combination of new debt in the amount of

NOK 110 million from Nordea Bank Abp, filial i Norge ("Nordea") and a rights

issue approved at an extraordinary general meeting of Navamedic on 14 July (the

"Rights Issue"). Navamedic has been assisted by DNB Carnegie a part of DNB Bank

ASA ("DNB Carnegie") and Advokatfirmaet Thommessen ("Thommessen") in connection

with the Acquisition, and Navamedic has been granted a bridge loan from Nordea

enabling completion of the Acquisition before completion of the Rights Issue.

Navamedic has retained DNB Carnegie, and Nordea Corporate Finance, a part of

Nordea Bank Abp, filial i Norge as managers and Thommessen as legal advisors for

the Rights Issue.

"We are very pleased closing this transaction with Navamedic and we are

confident that the Navamedic team will continue to grow the opioid substitution

business developed by dne pharma, in particular the Ventizolve® products" says

Geir Ove Engeset, CEO of dne pharma as.

For further information, please contact:

Lars Hjarrand, CFO, Mobile: +47 917 62 842 E-mail: Lars.Hjarrand@navamedic.com,

or

Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880 E-mail:

kathrine@navamedic.com.

About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's

quality of life by being a reliable supplier of high-quality prescription,

consumer health, and hospital products to hospitals and pharmacies. Our growing

product portfolio has been carefully selected to meet current public health

concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to

empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and

requirements of the countries where we are present. Our local insight and

competence enable us to understand the specific needs of each country where we

operate and ultimately to gain market access. This makes us a preferred partner

for international companies expanding their footprint across the Nordics and

Benelux regions, through either in-licensing or out-licensing. Navamedic has

been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is

headquartered in Oslo, Norway. For more information, please visit

www.Navamedic.com

Aboutdne pharma/Pharma Production

Prior to closing of the Transaction, dne pharmawas a Norwegian developer and

distributor of addiction and pain therapies, including opioid substitution

treatments and emergency overdose medications. dne pharma's wholly owned

subsidiary, Pharma Production AS, will continue to manufacture and supply the

product portfolio recently acquired by Navamedic, as well as concentrate on

contract manufacturing and development services, including analytical services,

supporting the long-term need for national pharmaceutical production capacity.

https://pharmaproduction.no (https://eur02.safelinks.protection.outlook.com/?url=

https%3A%2F%2Fpharmaproduction.no%2F&data=05%7C02%7Cole.henrik.eriksen%40navamedi

c.com%7C4a5078d22d7d47a7384e08ddc37340f3%7Ca5635f8e246b48e094e8806923fb2a69%7C0%7

C0%7C638881621997591634%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwL

jAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=qy

wslRKXkTVBe7yNmRJjZ2hkA9pxdsfG2qFLSu41gA8%3D&reserved=0).

This information is subject to the disclosure requirements pursuant to Section 5

-12 the Norwegian Securities Trading Act.